Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Clear all
Recruiting Phase 4 Interventional

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

NCT05270733
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

NCT05268016
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ME3183, Placebo
Drug
Lead sponsor
Meiji Pharma USA Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Rogers, Arkansas • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

NCT04042103
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Encino, California • Sanford, Florida • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis

NCT06555562
View directory record Official record
Conditions
Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Ultrasound Stimulation, Non-active ultrasound stimulation
Device
Lead sponsor
Surf Therapeutics
Industry
Eligibility
22 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

NCT01877668
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 22, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional Results available

PsA Treatment With hOKT3γ1 (Ala-Ala)

NCT00239720
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
hOKT3gamma1(Ala-Ala), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

NCT01320293
View directory record Official record
Conditions
Psoriasis
Interventions
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

NCT00601107
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Doxercalciferol, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Hot Springs, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

NCT01083758
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
San Diego, California • Jacksonville, Florida • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

Transitioning From Cyclosporine to Alefacept in Psoriasis

NCT00143806
View directory record Official record
Conditions
Psoriasis
Interventions
Transitioning patients from cyclosporine to alefacept
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 5, 2009 · Synced Oct 22, 2026, 5:40 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Adalimumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis

NCT04279119
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ARQ-151- cream 0.3%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Rogers, Arkansas • Fountain Valley, California • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

NCT02070965
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DFD01 Spray, Comp01 Lotion
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Encinitas, California • Encino, California • Santa Rosa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

NCT02933502
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
DSXS topical product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

NCT04128007
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
31
States / cities
Rogers, Arkansas • Fremont, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

NCT03210259
View directory record Official record
Conditions
Psoriasis
Interventions
Humira®, BI 695501
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Conditioning, the Placebo Effect, and Psoriasis

NCT00005922
View directory record Official record
Conditions
Psoriasis
Interventions
Partial schedule of pharmacotherapeutic reinforcement, Dose control for Arm B, Standard pharmacotherapeutic protocol
Behavioral · Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
2
States / cities
Palo Alto, California • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Oct 22, 2026, 5:40 AM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

NCT04099979
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Psoriasis Universalis, Psoriasis Face, Psoriasis Nail, Psoriatic Plaque, Psoriasis Diffusa, Psoriasis Punctata, Psoriasis Palmaris, Psoriasis Circinata, Psoriasis Annularis, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Geographica
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 3 Interventional

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00710580
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
ABT-874, etanercept, placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Psoriatic Arthritis

NCT02181673
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Glendale, Arizona • Mesa, Arizona • Huntington Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Denver, Colorado • Trumbull, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis

NCT00001797
View directory record Official record
Conditions
Psoriasis
Interventions
Recombinant human interleukin-10
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

NCT00192452
View directory record Official record
Conditions
Psoriasis
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
3
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 25, 2006 · Synced Oct 22, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

NCT02749370
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Scottsdale, Arizona • Beverly Hills, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 22, 2026, 5:40 AM EDT